TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-06-24 am EDT
3707.00 JPY   +0.05%
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
BU
06/22Takeda Signs 15-Year Lease with BioMed Realty
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour

06/28/2018 | 05:13am EDT
FILE PHOTO: The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc, failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favour, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal.

The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

The 130 member-group formed by ex-Takeda employees told Reuters earlier this month it did not expect its proposal to pass on Thursday.

It said it is working to persuade a third of shareholders to vote against a company proposal at a Takeda shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself.

Thursday's proposal reflected concerns among some investors about the attempt by Chief Executive Christophe Weber - the company's first foreign head - to clinch the largest-ever overseas purchase by a Japanese company.

The move would turn Takeda into one of the world's most indebted drugmakers, though Weber has insisted he can deliver savings to make the deal a big winner for shareholders.

Shares in Takeda and Shire both gained more than 2 percent following the AGM.

Takeda's shares are nevertheless down 18 percent at 4,524 yen since the company first said at the end of March it was considering bidding for Shire.

With uncertainty over whether the acquisition will be approved by shareholders and given concern over the size of the deal, "investors are taking a wait-and-see stance" towards Takeda stock, UBS analyst Atsushi Seki wrote in a note to clients last week.

In the note, UBS upgraded its recommendation on Takeda stock to "buy" from "neutral" and raised its price target to 6,700 yen. It also said a survey of 60 Japanese investors found 31 percent viewed the Shire deal negatively.

Proxy advisor Institutional Shareholder Services (ISS) recommended voting against Thursday's proposal, saying that while its "proponents raise legitimate concerns about the planned acquisition of Shire" there was an "absence of apparent grounds to cast doubt over the board's objectivity or competence".

(Reporting by Sam Nussey and Ritsuko Shimizu; Additional reporting by Ben Hirschler; Editing by Christopher Cushing)

By Sam Nussey


© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.05% 3707 Delayed Quote.18.17%
US DOLLAR / JAPANESE YEN (USD/JPY) -0.01% 135.16 Delayed Quote.17.16%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..
BU
06/22Takeda Signs 15-Year Lease with BioMed Realty
CI
06/17MARKETSCREENER'S WORLD PRESS REVIEW : June 17, 2022
06/17Takeda, Nintendo among Japanese firms quietly celebrating weak yen
RE
06/10Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
AQ
06/10TAKEDA PHARMACEUTICAL : Notice Concerning Disposal of Treasury Shares under the Long-Term ..
PU
06/09Takeda Pharmaceutical Says Dengue Vaccine Candidate 84% Effective Against Hospitalizati..
MT
06/09Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
BU
06/07Takeda Canada applauds Quebec's new Rare Disease Policy
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 25 833 M 25 833 M
Net income 2022 239 B 1 768 M 1 768 M
Net Debt 2022 3 299 B 24 416 M 24 416 M
P/E ratio 2022 24,2x
Yield 2022 4,86%
Capitalization 5 722 B 42 353 M 42 353 M
EV / Sales 2022 2,58x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 707,00 JPY
Average target price 4 468,13 JPY
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.17%42 353
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202